SSc in 2011: From mechanisms to medicines.

Abstract

Findings from ongoing studies of imatinib in systemic sclerosis (SSc) were eagerly awaited in 2011, but results from these clinical trials have so far been disappointing. However, progress in the understanding of the mechanisms that underlie SSc pathogenesis could provide clues to novel targets for 2012 and beyond.

• Authors: Luc Mouthon
• Journal: Nature reviews. Rheumatology (Nat Rev Rheumatol) Vol. 8 Issue 2 Pg. 72-4 (Jan 10 2012) ISSN: 1759-4804 [Electronic] United States
• PMID: 22231235 (Publication Type: Journal Article)

Chemical References

• Benzamides
• Piperazines
• Protein Kinase Inhibitors
• Pyrimidines
• Imatinib Mesylate

Topics

• Benzamides
• Blood Coagulation (drug effects)
• Clinical Trials as Topic
• Fibrosis (complications, drug therapy, physiopathology)
• Humans
• Imatinib Mesylate
• Molecular Targeted Therapy
• Piperazines (therapeutic use)
• Platelet Activation (drug effects)
• Protein Kinase Inhibitors (therapeutic use)
• Pyrimidines (therapeutic use)
• Scleroderma, Systemic (drug therapy, etiology, physiopathology)
• Treatment Outcome